Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase 3 DESTINY-Breast03 studyAnn. Oncol 2023 May 11;[EPub Ahead of Print], G Curigliano, K Dunton, M Rosenlund, M Janek, J Cathcart, Y Liu, PA Fasching, H Iwata
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.